title: A closer inspection of tedizolid - authors' reply.
authors: Clinical Development, Cubist Pharmaceuticals, San Diego, CA 92121, USA. Electronic address: philippe.prokocimer@cubist.com.
authors: Philippe
authors: P
authors: Prokocimer
authors: Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.
authors: G Ralph
authors: GR
authors: Corey
authors: Biometrics, InClin, San Mateo, CA, USA.
authors: Anita F
authors: AF
authors: Das
authors: Department of Emergency Medicine and Division of Infectious Diseases, Olive View-UCLA Medical Center, Sylmar, CA, USA.
authors: Gregory J
authors: GJ
authors: Moran
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage*; D010080:Oxazoles / Q000008:administration & dosage*; D023303:Oxazolidinones / Q000008:administration & dosage*; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; D023303:Oxazolidinones